Macquarie Group
ACHN

Macquarie Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Macquarie Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,900
Closed -$8K – 2496
2017
Q4 		$8K Buy
+2,900
New +$10.5K ﹤0.01% 2324
2015
Q4 		– Sell
-118,231
Closed -$817K – 1578
2015
Q3 		$817K Buy
118,231
+32,402
+38% +$264K ﹤0.01% 1167
2015
Q2 		$760K Buy
85,829
+2,450
+3% +$23.2K ﹤0.01% 1229
2015
Q1 		$822K Buy
+83,379
New +$1.04M ﹤0.01% 1200

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Macquarie Group's ACHN Position: Q1 2018 in Review

Macquarie Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 2,900 shares — an estimated $8K sold.

Macquarie Group first reported a position in ACHN in Q1 2015 and held it in 4 quarters. The position peaked at $822K in Q1 2015. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • Macquarie Group reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 2,900 Achillion Pharmaceuticals shares in Q1 2018, an estimated $8K.
  • Macquarie Group first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Macquarie Group's Achillion Pharmaceuticals position peaked at $822K in Q1 2015.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.